Non-alcoholic fatty liver disease (NAFLD) is currently 57 considered as one of the most common liver diseases in developed 58 countries. It includes the spectrum of simple steatosis and non-59 alcoholic steatohepatitis (NASH) [2] . Whereas simple steatosis 60 seems to be a benign and non-progressive condition, NASH is 61 recognized as a potentially progressive disease that may cause 62 cirrhosis, an end-stage liver disease, and hepatocellular carcinoma 63 (HCC) [18, 27] . While a low-calorie diet has been recommended 64 to treat obese NAFLD patients, it is sometimes difficult for many 65 patients to change their lifestyle. Accordingly, although efforts 66 are currently directed at overcome NASH, the optimal treatment 67 for NASH has not been established in clinical practice. 68
The current concept in the pathogenesis of NASH is the so-69 called "two-hit" theory, in which an initial metabolic disturbance, 70 such as insulin resistance (IR), causes steatosis, and then a second 71 pathogenic stimulus causes oxidative stress and reactive oxygen 72 species (ROS), leading to steatohepatitis [7, 30] . Several studies 73 have shown that iron may be the substrate of oxidative stress and 74 is probably responsible for the second hit in patients with NASH 75 [4, 9, 14] . In steatotic livers, saturation of β-oxidation by excess 76 free fatty acids ultimately leads to the production of hydrogen 77 peroxide, which in turn can mutate into highly reactive hydroxyl 78 radicals in the presence of free iron via the Fenton reaction [39] .
Indeed, there is much evidence that hepatic iron overload may be 80 a risk factor of HCC in patients with NASH [23, 24, 34] . 81 Therefore, antioxidant therapy by iron reduction, such as dietary 82 iron reduction, and phlebotomy for NASH have been reported [38, 83 44] . Moreover, injection therapy with deferoxamine (DFO), an 84 iron chelator, may reportedly reduce pre-neoplastic lesions in the 85 choline-deficient L-amino acid-defined (CDAA) rat model [31] . 86
Although DFO is beneficial as an antioxidant therapy for NASH, 87
it has limited efficacy due to its demanding therapeutic regimen 88 requiring subcutaneous administration or intravenous infusions, 89 leading to poor compliance by many patients. Recently, 90 deferasirox (DSX), an oral iron-chelator taken once daily, has 91 been developed as an effective alternative to DFO in the treatment 92 of transfusional iron overload in patients with certain types of 93 anemia, such as β-thalassemia, sickle cell disease and 94 myelodysplastic syndrome in clinical practice [1] . However, the 95 effect of DSX on NASH progression has yet to be clarified. 96
The renin-angiotensin system (RAS) plays an important 97 role in the regulation of local hemodynamics in several organs. It 98 has been reported that angiotensin-II (AT-II), an octapeptide 99 produced via enzymatic cleavage of angiotensin-I by an 100 angiotensin-I converting enzyme (ACE), plays an important role 101 in the progression of chronic liver diseases, including NASH [48] . 102
We and another group have shown that suppression of AT-II by aexperiments, all rats were anesthetized, and examined for the 152 study items. Hemoglobin (Hb) content and several serum markers, 153 such as alanine aminotransferase (ALT), albumin (Alb), total 154 bilirubin (T-bil) and iron concentrations, were assessed by routine 155 laboratory methods. Serum ferritin level was measured using 156 enzyme-linked immunosorbent assay (ELISA) kit (Mitsubishi 157
Chemical Safety Institute, Tokyo, Japan). 158
All animal procedures were performed according to 159 standard protocols and in compliance with standard 160 recommendations for the proper care and use of laboratory 161 animals. 162
Histological and Immunohistochemical Analyses 163
In all experimental groups, one section of the liver was 164 routinely stained with hematoxylin and eosin. Another section was 165 stained with Sirius-red (S-R) and Perls' Prussian blue to detect 166 fibrosis and iron deposition, respectively. Immunohistochemical 167 staining techniques of α-smooth muscle actin (α-SMA) (DAKO, 168
Kyoto, Japan), enzyme-altered pre-neoplastic lesions; namely, the 169 placental form of glutathione-S-transferase (GST-P) (MBL Co. 170
Ltd., Nagoya, Japan), and 8-hydroxydeoxyguanosine (8-OHdG) 171 (NIKKEN SEIL Co. Ltd., Tokyo, Japan), were performed as 172 described previously [20, 50] . To determine neovascularization, 173
we performed immunohistochemical detection of CD31 (BDneovascularization, using frozen sections as previously described 176
[52]. Semiquantitative analyses of fibrosis development and 177 immunopositive cell area of α-SMA, GST-P, 8-OHdG and CD31 178 were carried out with Adobe Photoshop software and National 179
Institutes of Health image software in 6 ocular fields 180 (magnification ×40) per specimen of 10 rats as described 181 elsewhere with minor modification [13, 48] . 
Statistical Analyses 243
To assess statistical significance of differences in the 244 quantitative data between groups, Bonferroni's multiple 245 comparison test was used after one-way ANOVA. This was
248

RESULTS
249
General Findings 250
Data from all experimental groups are shown in Table 1 . 251
Final body weight of CDAA-treated rats (G1) were less than 252 CSAA-treated rats (G5), while relative liver weights of G1 were 253 greater than those of G5. Serum ALT was significantly higher in 254 G1-G4 than in G5, whereas there was no significant difference 255 between in Alb and T-bil. No marked differences were observed in 256
Hb between experimental groups, although serum concentrations 257 of iron and ferritin were significantly higher in rats given the 258 CDAA diet. Among the CDAA-treated groups, the levels of 259 ferritin in G2 and G3 were less than in G1, and the level in G4 260 was less than in G2 and G3. Hepatic iron deposition almost 261 matched the serum levels of iron and ferritin. Moreover, LOS 262 and/or DSX did not affect liver function and several indices of 263 serum biochemistry in CSAA-fed normal rats. In addition, neither 264 histological inflammation nor hepatic TG content was 265 significantly altered by treatment with LOS and DSX (data not 266 shown). 267
Effects of LOS and DSX on the Liver Fibrosis Development 268
We first examined the effects of clinically comparable 269 doses of LOS and DSX on liver fibrosis induced by a CDAA diet. 270
As shown in (Fig. 4B and 4C) . 305
Effects of LOS and DSX on the Oxidative Stress in the Liver 306
Since ROS plays an important role in the progression of 307 NASH, we examined markers of oxidative DNA-damage and lipid 308 peroxidation; namely, 8-OHdG and MDA, respectively. As shown 309
in Fig. 5A , the number of 8-OHdG-immunopositive cells 310 markedly decreased in the LOS-(G2) and DSX-(G3) treated 311 groups than in G1. MDA content in the liver was also lower in G2 312 and G3 than in G1 (Fig. 5B) . The inhibitory effects of LOS and 313 DSX on 8-OHdG and MDA were of similar magnitude, and 314 combination treatment of LOS and DSX (G4) exerted a much 315 stronger inhibitory effect than either single agent. 316 
Effects of LOS and DSX on the Development of Pre-neoplastic 317
Lesions
